RecruitingNCT05303896
Investigating Myocardial Remodelling in the Failing Human Heart
Sponsor
Oslo University Hospital
Enrollment
200 participants
Start Date
May 30, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
Despite improvements in therapy, heart failure is a disease with high mortality and accelerating prevalence. To improve patient care, it is necessary to better understand the features and underlying mechanisms of myocardial remodeling; how it manifests in vivo and its underlying cellular and extracellular changes. The RELAX study will offer insight into myocardial remodeling, by comprehensively assessing function and structure of failing human hearts, and investigate its underlying cellular and extracellular changes.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria2
- Eligible for heart transplantation
- Willingness to participate in the present study and ability to understand and sign the written informed consent
Exclusion Criteria1
- Patients under the age of 18.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05303896
Related Trials
Mind Your Heart-II
NCT054311921 location
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
NCT071917301 location
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT0700216420 locations
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370641 locations
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288652 locations